Amgen Fights Income Allocations In $3.6B Tax Court Case

By Natalie Olivo · September 21, 2021, 8:09 PM EDT

Drugmaker Amgen is challenging a $3.6 billion tax bill in the U.S. Tax Court, accusing the IRS of misattributing profits its Puerto Rican subsidiary earned while manufacturing biopharmaceutical products under intercompany license...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login